A Mixture of U.S. Food and Drug Administration–Approved Monoaminergic Drugs Protects the Retina From Light Damage in Diverse Models of Night Blindness-Reference-Cited by-同舟云学术

A Mixture of U.S. Food and Drug Administration–Approved Monoaminergic Drugs Protects the Retina From Light Damage in Diverse Models of Night Blindness

Published:2019-04-04 Issue:5 Volume:60 Page:1442
ISSN:1552-5783
Container-title:Investigative Opthalmology & Visual Science
language:en
Short-container-title:Invest. Ophthalmol. Vis. Sci.

Author:

Leinonen Henri¹²,Choi Elliot H.¹²,Gardella Anthony³,Kefalov Vladimir J.⁴,Palczewski Krzysztof¹²

Affiliation:

1. Gavin Herbert Eye Institute and the Department of Ophthalmology, University of California-Irvine, Irvine, California, United States

2. Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio, United States

3. Department of Ophthalmology and Visual Sciences, Case Western Reserve University, Cleveland, Ohio, United States

4. Department of Ophthalmology and Visual Sciences, Washington University, St. Louis, Missouri, United States

Publisher

Association for Research in Vision and Ophthalmology (ARVO)

Subject

General Medicine

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A combination treatment based on drug repurposing demonstrates mutation-agnostic efficacy in pre-clinical retinopathy models;Nature Communications;2024-07-15

2. Synthesis and Biological Analysis of Iso-dimethyltryptamines in a Model of Light-Induced Retinal Degeneration;ACS Medicinal Chemistry Letters;2024-06-13

3. Compound heterozygous mutations in GRM6 causing complete Schubert-Bornschein type congenital stationary night blindness;Heliyon;2024-03

4. Distinct mouse models of Stargardt disease display differences in pharmacological targeting of ceramides and inflammatory responses;Proceedings of the National Academy of Sciences;2023-12-08

5. Galanin receptor 3 − A new pharmacological target in retina degeneration;Pharmacological Research;2023-02